First-in-human, multicenter phase Ⅰ study of TGRX-326 in patients with advanced ALK-positive non-small cell lung cancer.
Published date:
05/25/2023
Excerpt:
Eleven ALK mutations were detected in 16 pts (either alone or in combination); 50.0% pts achieved PR….TGRX-326 demonstrated antitumor activity against multiple ALK mutations including G1202R.